New Technologies Conquering Drug Delivery Obstacles in Acute Ocular Pain Treatment Landscape

1. Maximizing Treatment Benefits in Acute Ocular Pain: The Potential of New Drug Delivery Technologies One of the most frequent medical complaints in emergency clinics is ocular pain. Eye pain caused by debilitating eye disorders and post-ocular surgery affects the majority of the older population. Acute and chronic eye pain can be generally categorised; chronic eye pain is defined as lasting more than three months. Furthermore, the primary source of acute ocular pain is nociceptive pain. Traditional acute ocular pain treatment options with significant unmet needs Topical anesthetics, corticosteroids, ointments, gels, or drops are available as treatments for acute ocular pain. Yet, it has proven difficult for doctors to directly prescribe or dispense these medicines to patients due to their relationship with side effects and other drawbacks. Despite being effective, topical anesthetics frequently cause permanent corneal blindness. In addition, the frequent application of eye drops, the short contact duration, and the likelihood that the

2. acute ocular pain medication will reach the target site are three main issues with the present acute ocular pain treatment. Are we managing the pain efficiently? In the past ten years, we have made significant strides in our understanding of neurophysiology, which has improved the methods for treating acute ocular pain The US FDA recently approved treatments like DEXTENZA, INVELTYS, and LOTEMAX SM to treat ocular inflammation and pain after ophthalmic surgery and cataract surgery to assist lessen the discomfort. Novel drug delivery systems enhancing ocular residence time and bioavailability Acute ocular pain therapies that are soon to be developed will benefit from advances in technology that address a number of problems with existing acute ocular pain treatments, including compliance and contact time with layers of ocular tissue. By 2025, many new competitors are anticipated to enter the market for acute ocular pain treatments, including OCS-01 (Oculis SA), SURF-201 (Surface Ophthalmics), APP13007 (Formosa Pharmaceuticals), SDN-037 (Visiox Pharma), DEXYCU (EyePoint Pharmaceuticals), and SVT-15473 (Salvat Laboratories). To stand out from the competition, major pharma companies that treat acute ocular pain use various drug delivery systems and platforms. Pharma behemoths continue to be interested in the advantages of corticosteroids' anti-inflammatory effects. Nonetheless, corticosteroid side effects must be taken into consideration despite their potentially beneficial activity. Moreover, the present pipeline for treating acute ocular pain focuses mostly on pain associated with cataracts and eye procedures. As a result, the market for treating acute ocular pain urgently needs novel medicines that deal with various ocular ailments and overcome the drawbacks of corticosteroids. Related Reports B Cell Chronic Lymphocytic Leukemia Market DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. B-Cell Lymphomas Market DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Behcet’s Syndrome Market DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the

3. market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom. Neoantigen-based Personalized Cancer therapeutic Vaccines DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Glioblastoma Multiforme Market DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Latest Reports By DelveInsight Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting Recent Blog’s By DelveInsight: ● ● ● ● Insights Into The Cutaneous T-cell Lymphoma Treatment Market Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape Emerging Role of Digital Health in the Field of Oncology How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape How are Technological Trends and Innovations Reshaping the Dementia Care Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Evaluating the Key Trends and Technologies Shaping the Future of Dentistry ● ● ● ● ●